STAAR Surgical

STAA

Market cap $1.35B

Overview Fund Activity

27.16 USD

-0.07

0.26%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

27.16

0.00

0%

1 day

-0.26%

5 days

-1.95%

1 month

-2.97%

3 months

63.32%

6 months

54.14%

Year to date

12.7%

1 year

-15.6%

5 years

-50.47%

10 years

228.81%

About: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Employees: 1,211

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

82% more call options, than puts

Call options by funds: $2.83M | Put options by funds: $1.55M

18% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 56

2.8% more ownership

Funds ownership: 105.95% [Q1] → 108.75% (+2.8%) [Q2]

2% less capital invested

Capital invested by funds: $922M [Q1] → $905M (-$17.3M) [Q2]

9% less funds holding

Funds holding: 185 [Q1] → 169 (-16) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

41% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 34

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

34% downside

Avg. target

$26

6% downside

High target

$28

3% upside

4 analyst ratings

0 positive

0%

4 neutral

100%

0 negative

0%

Stifel Thomas Stephan	$28	Hold Downgraded	7 Aug 2025
Canaccord Genuity Jon Young	$28	Hold Maintained	6 Aug 2025
Sidoti & Co. James Sidoti	$28	Neutral Downgraded	5 Aug 2025
Mizuho Anthony Petrone	$18	Neutral Maintained	16 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about STAA published over the past 30 days

STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Alcon (SIX/NYSE: ALC). STAAR will hold a Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote to adopt the.

STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders

Shareholder Alert: The Ademi Firm Continues to Investigate Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm continues to investigate STAAR (NASDAQ: STAA) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of STAAR will receive $28 per share in cash, valuing the transaction at approximately.

Shareholder Alert: The Ademi Firm Continues to Investigate Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders

STAA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of STAAR Surgical Company is Fair to Shareholders

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of STAAR Surgical Company (NASDAQ: STAA) to Alcon for $28.00 per share in cash is fair to STAAR shareholders.

STAA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of STAAR Surgical Company is Fair to Shareholders

Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical

SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).

Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical

STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, issued the following statement: “The merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day prior to the agreement being announced) and a 59% premium to STAAR's 90-day Volume Weight.

STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger

Broadwood Announces Intent to Vote Against Acquisition of STAAR Surgical by Alcon

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (together, “Broadwood”) currently intend to vote against the proposed acquisition of STAAR Surgical Company by Alcon Inc. Broadwood is STAAR's largest shareholder, owning 27.3% of STAAR's common shares outstanding. Broadwood has owned STAAR shares for over 30 years, has been the company's largest shareholder since 2007, and has long been one of STAAR's largest and most supportive stockholders, including by providing capital.

Broadwood Announces Intent to Vote Against Acquisition of STAAR Surgical by Alcon

Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

GENEVA--(BUSINESS WIRE)--Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical.

Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

GENEVA--(BUSINESS WIRE)--Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical.

Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

Zacks Investment Research

Staar Surgical (STAA) International Revenue in Focus: Trends and Expectations

Examine Staar Surgical's (STAA) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Staar Surgical (STAA) International Revenue in Focus: Trends and Expectations

Shareholder Alert: The Ademi Firm Investigates Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating STAAR (NASDAQ: STAA) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of STAAR will receive $28 per share in cash, valuing the transaction at approximately $1.5 bil.

Shareholder Alert: The Ademi Firm Investigates Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders

See News Rankings

Charts implemented using Lightweight Charts™